Beitelshees AL, et al. Sodium-glucose cotransporter 2 inhibitors: A case study in translational research. Diabetes 2019; 68:1109–1120. doi: 10.2337/dbi18-0006

• Crossref
Beitelshees AL, Sodium-glucose cotransporter 2 inhibitors: A case study in translational research. Diabetes 2019; 68:1109–1120. doi: 10.2337/dbi18-000610.2337/dbi18-0006)| false
• Search Google Scholar
• Export Citation

Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377:644–657. doi: 10.1056/NEJMc1712572

• Crossref
Neal B, Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377:644–657. doi: 10.1056/NEJMc171257210.1056/NEJMoa1611925)| false
• Search Google Scholar
• Export Citation

Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117–2128. doi: 10.1056/NEJMc1600827

• Crossref
Zinman B, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117–2128. doi: 10.1056/NEJMc160082710.1056/NEJMoa1504720)| false
• Search Google Scholar
• Export Citation

Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380:347–357. doi: 10.1056/NEJMoa1812389

• Crossref
Wiviott SD, Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380:347–357. doi: 10.1056/NEJMoa181238910.1056/NEJMoa1812389)| false
• Search Google Scholar
• Export Citation

Lin YH, et al. Renal and glucose-lowering effects of empagliflozin and dapagliflozin in different chronic kidney disease stages. Front Endocrinol (Lausanne) 2019; 10:820. doi: 10.3389/fendo.2019.00820

• Crossref
Lin YH, Renal and glucose-lowering effects of empagliflozin and dapagliflozin in different chronic kidney disease stages. Front Endocrinol (Lausanne) 2019; 10:820. doi: 10.3389/fendo.2019.0082010.3389/fendo.2019.00820)| false
• Search Google Scholar
• Export Citation

Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295–2306. doi: 10.1056/NEJMoa1811744

• Crossref
Perkovic V, Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295–2306. doi: 10.1056/NEJMoa181174410.1056/NEJMoa1811744)| false
• Search Google Scholar
• Export Citation

McMurray JV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381:1995–2008. doi: 10.1056/NEJMoa1911303

• Crossref
McMurray JV, Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381:1995–2008. doi: 10.1056/NEJMoa191130310.1056/NEJMoa1911303)| false
• Search Google Scholar
• Export Citation

Hahn K, et al. Acute kidney injury from SGLT2 inhibitors: Potential mechanisms. Nat Rev Nephrol 2016; 12:711–712. doi: 10.1038/nrneph.2016.159

• Crossref
Hahn K, Acute kidney injury from SGLT2 inhibitors: Potential mechanisms. Nat Rev Nephrol 2016; 12:711–712. doi: 10.1038/nrneph.2016.15910.1038/nrneph.2016.159)| false
• Search Google Scholar
• Export Citation

Nadkarni GN, et al. Acute kidney injury in patients on SGLT2 inhibitors: A propensity-matched analysis. Diabetes Care 2017; 40:1479–1485. doi: 10.2337/dc17-1011

• Crossref
Nadkarni GN, Acute kidney injury in patients on SGLT2 inhibitors: A propensity-matched analysis. Diabetes Care 2017; 40:1479–1485. doi: 10.2337/dc17-101110.2337/dc17-1011)| false
• Search Google Scholar
• Export Citation

Skrtić M, et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 2014; 57:2599–2602. doi: 10.1007/s00125-014-3396-4

• Crossref
Skrtić M, Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 2014; 57:2599–2602. doi: 10.1007/s00125-014-3396-410.1007/s00125-014-3396-4)| false
• Search Google Scholar
• Export Citation

Lytvyn Y, et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 2015; 308:F77–F83. doi: 10.1152/ajprenal.00555.2014

• Crossref
Lytvyn Y, Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 2015; 308:F77–F83. doi: 10.1152/ajprenal.00555.201410.1152/ajprenal.00555.2014)| false
• Search Google Scholar
• Export Citation

Hahn K, et al. Serum uric acid and acute kidney injury: A mini review. J Adv Res 2017; 8:529–536. doi: 10.1016/j.jare.2016.09.006

• Crossref
Hahn K, Serum uric acid and acute kidney injury: A mini review. J Adv Res 2017; 8:529–536. doi: 10.1016/j.jare.2016.09.00610.1016/j.jare.2016.09.006)| false
• Search Google Scholar
• Export Citation

O’Neill J, et al. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol 2015; 309:F227–F234. doi: 10.1152/ajprenal.00689.2014

• Crossref
O’Neill J, Acute SGLT inhibition normalizes O₂ tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol 2015; 309:F227–F234. doi: 10.1152/ajprenal.00689.201410.1152/ajprenal.00689.2014)| false
• Search Google Scholar
• Export Citation

Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation 2019; 139:1985–1987. doi: 10.1161/CIRCULATIONAHA.118.038881

• Crossref
Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation 2019; 139:1985–1987. doi: 10.1161/CIRCULATIONAHA.118.03888110.1161/CIRCULATIONAHA.118.038881)| false
• Search Google Scholar
• Export Citation

Cantarelli C, et al. Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity. Am J Transplant 2019; 19:2407–2414. doi: 10.1111/ajt.15369

• Crossref
Cantarelli C, Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity. Am J Transplant 2019; 19:2407–2414. doi: 10.1111/ajt.1536910.1111/ajt.15369)| false
• Search Google Scholar
• Export Citation

Dekkers CCJ, et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab 2018; 20:1988–1993. doi: 10.1111/dom.13301

• Crossref
Dekkers CCJ, Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab 2018; 20:1988–1993. doi: 10.1111/dom.1330110.1111/dom.13301)| false
• Search Google Scholar
• Export Citation

Neuen BL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol 2019; 7:845–854. doi: 10.1016/S2213-8587(19)30256-6

• Crossref
Neuen BL, SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol 2019; 7:845–854. doi: 10.1016/S2213-8587(19)30256-610.1016/S2213-8587(19)30256-6)| false
• Search Google Scholar
• Export Citation

Gilbert RE, Thorpe KE. Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials. Diabetes Obes Metab 2019; 21:1996–2000. doi: 10.1111/dom.13754

• Crossref
Gilbert RE, Thorpe KE. Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials. Diabetes Obes Metab 2019; 21:1996–2000. doi: 10.1111/dom.1375410.1111/dom.13754)| false
• Search Google Scholar
• Export Citation

Menne J, et al. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis. PLoS Med 2019; 16:e1002983. doi: 10.1371/journal.pmed.1002983

• Crossref
Menne J, Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis. PLoS Med 2019; 16:e1002983. doi: 10.1371/journal.pmed.100298310.1371/journal.pmed.1002983)| false
• Search Google Scholar
• Export Citation

Singh P, et al. Renal oxygenation and haemodynamics in acute kidney injury and chronic kidney disease. Clin Exp Pharmacol Physiol 2013; 40:138–147. doi: 10.1111/1440-1681.12036

• Crossref
Singh P, Renal oxygenation and haemodynamics in acute kidney injury and chronic kidney disease. Clin Exp Pharmacol Physiol 2013; 40:138–147. doi: 10.1111/1440-1681.1203610.1111/1440-1681.12036)| false
• Search Google Scholar
• Export Citation

Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney. Nat Rev Nephrol 2017; 13:629–646. doi: 10.1038/nrneph.2017.107

• Crossref
Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney. Nat Rev Nephrol 2017; 13:629–646. doi: 10.1038/nrneph.2017.10710.1038/nrneph.2017.107)| false
• Search Google Scholar
• Export Citation

Mack M, Yanagita M. Origin of myofibroblasts and cellular events triggering fibrosis. Kidney Int 2015; 87:297–307. doi: 10.1038/ki.2014.287

• Crossref
Mack M, Yanagita M. Origin of myofibroblasts and cellular events triggering fibrosis. Kidney Int 2015; 87:297–307. doi: 10.1038/ki.2014.28710.1038/ki.2014.287)| false
• Search Google Scholar
• Export Citation

Sayour AA, et al. Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. J Transl Med 2019; 17:127. doi: 10.1186/s12967-019-1881-8

• Crossref
Sayour AA, Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. J Transl Med 2019; 17:127. doi: 10.1186/s12967-019-1881-810.1186/s12967-019-1881-8)| false
• Search Google Scholar
• Export Citation

Chang YK, et al. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One 2016; 11:e0158810. doi: 10.1371/journal.pone.0158810

• Crossref
Chang YK, Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One 2016; 11:e0158810. doi: 10.1371/journal.pone.015881010.1371/journal.pone.0158810)| false
• Search Google Scholar
• Export Citation

Fujita Y, et al. Low erythropoietin levels predict faster renal function decline in diabetic patients with anemia: A prospective cohort study. Sci Rep 2019; 9:14871. doi: 10.1038/s41598-019-51207-8

• Crossref
Fujita Y, Low erythropoietin levels predict faster renal function decline in diabetic patients with anemia: A prospective cohort study. Sci Rep 2019; 9:14871. doi: 10.1038/s41598-019-51207-810.1038/s41598-019-51207-8)| false
• Search Google Scholar
• Export Citation

Chu C, et al. The SGLT2 inhibitor empagliflozin might be a new approach for the prevention of acute kidney injury. Kidney Blood Press Res 2019; 44:149–157. doi: 10.1159/000498963

• Crossref
Chu C, The SGLT2 inhibitor empagliflozin might be a new approach for the prevention of acute kidney injury. Kidney Blood Press Res 2019; 44:149–157. doi: 10.1159/00049896310.1159/000498963)| false
• Search Google Scholar
• Export Citation

Neumiller JJ, Kalyani RR. How does CREDENCE inform best use of SGLT2 inhibitors in CKD? Clin J Am Soc Nephrol 2019; 14:1667–1669. doi: 10.2215/CJN.05340419

• Crossref
Neumiller JJ, Kalyani RR. How does CREDENCE inform best use of SGLT2 inhibitors in CKD? Clin J Am Soc Nephrol 2019; 14:1667–1669. doi: 10.2215/CJN.0534041910.2215/CJN.05340419)| false
• Search Google Scholar
• Export Citation